Scholar Rock Holding Corporation Common Stock

Day range

$41.15 – $41.93

Open

$41.64

Prev close

$41.49

Volume

1.68M

Market cap

$5.05B

Shares out

121.79M

P/E

—

P/S

—

P/B

19.91

P/FCF

—

ROE

-161.0%

ROA

-78.0%

Debt/Equity

0.77

Div yield

0.00%

As of Oct 23, 2026

• Regulatory decisionSep 15, 2026

  the U.S. Food and Drug Administration ("FDA") has approved ISEMBYLD™ (apitegromab-mstn) for the treatment of spinal muscular atrophy in adults and children 2 years of age and older who are currently receiving a survival motor neuron 2 (SMN2)-targeted treatment.

• Investor presentationSep 14, 2026

  A copy of the Company's presentation materials in connection with the announcement is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

• Underwriting agreementAug 6, 2026

  Scholar Rock Holding Corporation (the 'Company') entered into an Open Market Sale AgreementSM, dated November 14, 2022, with Jefferies LLC ('Jefferies') relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock...through Jefferies as sales agent (the 'ATM Program').

• Investor presentationMay 7, 2026

  The Company will utilize slides during its conference call scheduled for 8:00 am ET on May 7, 2026 to announce its financial and operating results for the fiscal quarter ended March 31, 2026 and to provide a business update. A copy of the slides is furnished as Exhibit 99.2.

• Preliminary resultsJan 12, 2026

  Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2025, the Company announced on January 12, 2026, that it estimates it had approximately $365 million (unaudited) of cash, cash equivalents and marketable securities as of December 31, 2025.

Days to cover

9.3

Short interest

22.72M

Avg volume

2.44M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA Treatment
  positiveGlobeNewswire Inc.· Sep 11, 2026
• Scholar Rock Chief Scientific Officer Conducts Multiple Sales Throughout January 2026
  neutralThe Motley Fool· Feb 1, 2026
• Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away
  neutralThe Motley Fool· Dec 3, 2025
• FDA OKs Novartis SMA Treatment As First Gene Therapy Option For Kids, Teens And Adults
  positiveBenzinga· Nov 25, 2025
• Why Scholar Rock Stock Got Socked on Monday
  negativeThe Motley Fool· Oct 13, 2025